4.90
0.20 (4.26%)
| 前收盘价格 | 4.70 |
| 收盘价格 | 4.80 |
| 成交量 | 3,599 |
| 平均成交量 (3个月) | 18,676 |
| 市值 | 48,470,704 |
| 市盈率 (P/E TTM) | 30.63 |
| 股市价格/股市净资产 (P/B) | 78.09 |
| 52周波幅 | |
| 利润日期 | 20 Mar 2025 - 24 Mar 2025 |
| 营业利益率 (TTM) | 29,092.86% |
| 稀释每股收益 (EPS TTM) | -1.51 |
| 季度收入增长率 (YOY) | -51.70% |
| 季度盈利增长率 (YOY) | -19.50% |
| 总债务/股东权益 (D/E MRQ) | 90.75% |
| 流动比率 (MRQ) | 2.40 |
| 营业现金流 (OCF TTM) | -17.14 M |
| 杠杆自由现金流 (LFCF TTM) | -7.94 M |
| 资产报酬率 (ROA TTM) | -124.04% |
| 股东权益报酬率 (ROE TTM) | -485.36% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Serina Therapeutics, Inc. | - | - |
AIStockmoo 评分
| 分析师共识 | 0.0 |
| 内部交易活动 | 3.0 |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 0.5 |
| 平均 | 0.30 |
|
Serina Therapeutics, Inc. operates as a pharmaceutical company that develops drugs to treat neurological diseases, cancer, and pain. The company develops a pipeline of partnered programs applying POZ platform to cancer, pain, refractory epilepsy, and movement disorders, such as Parkinson's disease and restless leg syndrome. Its pipeline includes SER-214, a solution for Parkinson's disease/restless leg syndrome; SER-226, a post-operative pain management solution; SER-228 for refractory epilepsy; SER-232 for chemotherapy-induced nausea and vomiting; and polymer poly (2-oxazoline) or POZ drug delivery polymer technology. Serina Therapeutics, Inc. was incorporated in 2006 and is based in Huntsville, Alabama. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 61.81% |
| 机构持股比例 | 3.21% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Broadwood Capital Inc | 31 Dec 2024 | 85,219 |
| Waverly Advisors, Llc | 31 Dec 2024 | 67,492 |
| Keel Point, Llc | 31 Dec 2024 | 17,774 |
| Piscataqua Savings Bank | 31 Dec 2024 | 28 |
| Riggs Asset Managment Co. Inc. | 31 Dec 2024 | 24 |
该时间范围内无数据。
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合